Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis.
A trial of antiplatelet therapy (slow-release aspirin and dipyridamole) in mesangial IgA glomerulonephritis was conducted. Vitamin B was given to the control group. Altogether, 38 patients were observed for a mean of 33.2 months. Antiplatelet therapy did not favorably modify the course of mesangial IgA glomerulonephritis. The rate of progression of the disease, measured by the slope of reciprocals of serum creatinine v time plots, correlated significantly with the severity of tissue damage as assessed by an arbitrary morphologic score from renal biopsy specimens.
D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D003692:Delayed-Action Preparations; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005920:Glomerular Mesangium; D005922:Glomerulonephritis, IGA / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D011897:Random Allocation
D003692:Delayed-Action Preparations; D007074:Immunoglobulin G; D004176:Dipyridamole; D003404:Creatinine; D001241:Aspirin